Insurers grapple with expanding overage for weight loss medications; a new analysis reveals a potential correlation between COVID-19 vaccinations and various adverse effects (AEs); reshaping Medicaid programs remains an ongoing debate about ensuring health care access.
Weight Loss Drugs Reaching Coverage Milestones Under the ACA
As the obesity crisis continues, semaglutide (Wegovy) has gained attention for its effectiveness in weight loss, according to Stat. However, its high cost—more than $16,000 annually—poses challenges for insurers under the Affordable Care Act, (ACA), raising questions about accessibility and affordability for patients seeking the treatment. Despite hurdles, efforts are underway to expand coverage under the act, potentially reshaping the landscape of weight loss interventions.
Multicountry COVID Study Links Vaccines, Potential Adverse Effects
The most extensive study conducted across several countries has identified a correlation between COVID-19 vaccines and potential adverse effects, including myocarditis and Guillain-Barré syndrome, according to The Hill. The findings highlight the importance of ongoing monitoring and research to ensure the safety and efficacy of worldwide vaccination campaigns, underscoring the need for transparent communication and vigilant surveillance in the ongoing global effort to combat the pandemic.
Trump Pushes States to Overhaul Medicaid Amid Political Tensions
Former President Donald Trump's renewed advocacy for Medicaid overhaul has placed pressure on states to navigate complex health care decisions, including potential changes to eligibility criteria and finding of health safety-net programs, according to Politico. Amid concerns over access and the federal-state partnership, this development amplifies the ongoing debate over Medicaid's role in ensuring health care access for vulnerable populations and highlights the overall complexities of state-level health care policymaking.
Study Highlights Significant Increases in Utilization, Spending on DMD Drugs in Medicaid
May 17th 2024The findings add to recent research on the growing utilization, expenditure, and prices of Duchenne muscular dystrophy (DMD) therapies in the current landscape, an area health care policy could potentially address.
Read More
Frameworks for Advancing Health Equity: Urban Health Outreach
May 9th 2024In the series debut episode of "Frameworks for Advancing Health Equity," Mary Sligh, CRNP, and Chelsea Chappars, of Allegheny Health Network, explain how the Urban Health Outreach program aims to improve health equity for individuals experiencing homelessness.
Listen
Perioperative Nivolumab Boosts NSCLC Survival: CheckMate 77T Trial
May 16th 2024This interim analysis of the CheckMate 77T trial, outcomes were compared between adult patients receiving neoadjuvant nivolumab plus chemotherapy or neoadjuvant chemotherapy plus placebo for resectable non–small cell lung cancer (NSCLC).
Read More